Literature DB >> 18311820

Dysfunctional CD4+,CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells.

Bing Yan1, Shuang Ye, Guangjie Chen, Miao Kuang, Nan Shen, Shunle Chen.   

Abstract

OBJECTIVE: To explore whether there are extrinsic factors that impair the suppressive function of CD4+,CD25+ regulatory T cells in patients with untreated active systemic lupus erythematosus (SLE).
METHODS: We studied 15 patients with untreated active SLE, 10 patients with SLE in remission, and 15 healthy control subjects. Percentages of CD4+,CD25+,FoxP3+ Treg cells and levels of forkhead box P3 (FoxP3) protein were analyzed by flow cytometry. Expression of messenger RNA (mRNA) for FoxP3 in purified Treg cell populations was assessed by real-time polymerase chain reaction analysis. Experiments examining Treg cell function in SLE were designed to distinguish primary from secondary T cell dysfunction. Levels of interferon-alpha (IFNalpha) in supernatants from the function assays were determined with an IFN-stimulated response element-luciferase reporter assay.
RESULTS: The percentage of CD4+,CD25+, FoxP3+ cells in peripheral blood was significantly increased in SLE patients as compared with controls (mean +/- SEM 9.11 +/- 0.73% versus 4.78 +/- 0.43%; P < 0.0001). We found no difference in FoxP3 expression at either the mRNA or protein level in any CD4+,CD25+ T cell subset from SLE patients as compared with controls. Antigen-presenting cells (APCs) from SLE patients were responsible for decreased Treg cell activity and could also render dysfunctional Treg cells from healthy control subjects. CD4+,CD25+ Treg cells from SLE patients exhibited normal suppressive activity when cultured with APCs from healthy controls. A partial Treg cell blockade effect was induced by the high levels of IFNalpha derived from SLE patient APCs.
CONCLUSION: We suggest that blockade of Treg cell-mediated suppression by IFNalpha-producing APCs in SLE patients may contribute to a pathogenic loss of peripheral tolerance in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18311820     DOI: 10.1002/art.23268

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  84 in total

Review 1.  Induced Foxp3(+) regulatory T cells: a potential new weapon to treat autoimmune and inflammatory diseases?

Authors:  Qin Lan; Huimin Fan; Valerie Quesniaux; Bernhard Ryffel; Zhongmin Liu; Song Guo Zheng
Journal:  J Mol Cell Biol       Date:  2011-11-22       Impact factor: 6.216

2.  Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.

Authors:  Arnold I Chin; Andrea K Miyahira; Anthony Covarrubias; Juli Teague; Beichu Guo; Paul W Dempsey; Genhong Cheng
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

3.  Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.

Authors:  Hiroshi Kato; Andras Perl
Journal:  J Immunol       Date:  2014-03-28       Impact factor: 5.422

4.  Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.

Authors:  Keisa W Mathis; Erin B Taylor; Michael J Ryan
Journal:  Pharmacol Res       Date:  2017-04-08       Impact factor: 7.658

5.  Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety.

Authors:  Jorge Paz Rodriguez; Michael P Murphy; Soonjun Hong; Marialaura Madrigal; Keith L March; Boris Minev; Robert J Harman; Chien-Shing Chen; Ruben Berrocal Timmons; Annette M Marleau; Neil H Riordan
Journal:  Int Arch Med       Date:  2012-02-08

Review 6.  Natural regulatory T cells in autoimmunity.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Autoimmunity       Date:  2010-11-23       Impact factor: 2.815

7.  Regulatory T cells vs Th17: differentiation of Th17 versus Treg, are the mutually exclusive?

Authors:  Song Guo Zheng
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

8.  IFN-τ Alleviates Lipopolysaccharide-Induced Inflammation by Suppressing NF-κB and MAPKs Pathway Activation in Mice.

Authors:  Haichong Wu; Gan Zhao; Kangfeng Jiang; Xiuying Chen; Guangze Rui; Changwei Qiu; Mengyao Guo; Ganzhen Deng
Journal:  Inflammation       Date:  2016-06       Impact factor: 4.092

Review 9.  Induction of immune tolerance by activation of CD8+ T suppressor/regulatory cells in lupus-prone mice.

Authors:  Brian J Skaggs; Ram Pyare Singh; Bevra H Hahn
Journal:  Hum Immunol       Date:  2008-09-24       Impact factor: 2.850

10.  IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type I IFN-dependent inflammatory disease.

Authors:  Shivani Srivastava; Lisa K Koch; Daniel J Campbell
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.